Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Riociguat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1A1 known ✓ | Q02108 | 11/20 | 0.60 |
| ▸ | GUCY1B1 known ✓ | Q02153 | 11/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 4/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | PDE5A | O76074 | 7/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Riociguat SCHEMBL29419573 | 1.00 | KCNH2 (1.00) | KCNH2ADORA3GUCY1A1GUCY1B1PDE5A | |
| Riociguat SCHEMBL29379983 | 1.00 | KCNH2 (1.00) | KCNH2ADORA3GUCY1A1GUCY1B1PDE5A | |
| Riociguat SCHEMBL29357210 | 1.00 | KCNH2 (1.00) | KCNH2ADORA3GUCY1A1GUCY1B1PDE5A | |
| Riociguat SCHEMBL15744746 | 0.94 | KCNH2 (0.89) | KCNH2ADORA3GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL31037564 | 0.94 | KCNH2 (0.88) | KCNH2ADORA3GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL12593410 | 0.92 | KCNH2 (0.86) | KCNH2ADORA3GUCY1A1GUCY1B1PDE5A | |
| Riociguat SCHEMBL12364300 | 0.92 | KCNH2 (0.84) | KCNH2ADORA3GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL5477000 | 0.92 | KCNH2 (0.84) | KCNH2ADORA3GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL256202 | 0.91 | KCNH2 (0.84) | KCNH2ADORA3GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL31037565 | 0.91 | KCNH2 (0.83) | KCNH2ADORA3GUCY1A1GUCY1B1PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 336 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1506193-B9 | CARBAMATE-SUBSTITUTED PYRAZOLOPYRIDINES | ADVERIO PHARMA GMBH (DE) | 2026-02-18 | — | — | EP | claimed |
| EP-1506193-B3 | CARBAMATE-SUBSTITUTED PYRAZOLOPYRIDINES | ADVERIO PHARMA GMBH (DE) | 2025-12-03 | — | — | EP | claimed |
| EP-3790546-B1 | NON-STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS ALONE OR IN COMBINATION FOR USE IN THE TREATMENT OF MUSCULAR OR NEUROMUSCULAR DISEASES | BAYER AG (DE) | 2024-08-21 | — | — | EP | claimed |
| US-11508483-B2 | Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group | ADVERIO PHARMA GMBH (DE) | 2022-11-22 | — | — | US | claimed |
| US-11439628-B2 | Use of non-steroidal mineralocorticoid receptor antagonists alone or in combination for the treatment of muscular or neuromuscular diseases | BAYER AKTIENGESELLSCHAFT (DE) | 2022-09-13 | — | — | US | claimed |
| US-20210121447-A1 | The Use of Non-Steroidal Mineralocorticoid Receptor Antagonists Alone or in Combination for the Treatment of Muscular or Neuromuscular Diseases | BAYER AKTIENGESELLSCHAFT (DE) | 2021-04-29 | — | — | US | claimed |
| US-10568895-B2 | Methods and materials for treating calcific aortic valve stenosis | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2020-02-25 | — | — | US | claimed |
| EP-3574905-A1 | METHOD OF IDENTIFYING A SUBGROUP OF PATIENTS SUFFERING FROM DCSSC WHICH BENEFITS FROM A TREATMENT WITH SGC STIMULATORS AND SGC ACTIVATORS IN A HIGHER DEGREE THAN A CONTROL GROUP | Adverio Pharma GmbH (DE) | 2019-12-04 | — | — | EP | claimed |
| EP-3566704-A1 | THE USE OF NON-STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS ALONE OR IN COMBINATION FOR THE TREATMENT OF MUSCULAR OR NEUROMUSCULAR DISEASES | Bayer Aktiengesellschaft (DE) | 2019-11-13 | — | — | EP | claimed |
| EP-3291811-B1 | THE USE OF SGC STIMULATORS, SGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF DIGITAL ULCERS (DU) CONCOMITANT TO SYSTEMIC SCLEROSIS (SSC) | Bayer Pharma AG (DE) | 2019-08-07 | — | — | EP | claimed |
| US-20100210643-A1 | sGC STIMULATORS, sGC ACTIVATORS AND COMBINATIONS FOR THE TREATMENT OF UROLOGICAL DISORDERS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-19 | — | — | US | claimed |
| WO-2010081647-A2 | SGC STIMULATORS OF SGC ACTIVATORS IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-07-22 | — | — | WO | claimed |
| US-20100113452-A1 | COMPOUNDS FOR TREATING PULMONARY HYPERTENSION | BAYER HEALTHCARE AG (DE) | 2010-05-06 | — | — | US | claimed |
| EP-2010173-A1 | COMPOUNDS FOR TREATING PULMONARY HYPERTENSION | Bayer HealthCare AG (DE) | 2009-01-07 | — | — | EP | claimed |
| WO-2007118602-A1 | COMPOUNDS FOR TREATING PULMONARY HYPERTENSION | BAYER HEALTHCARE AG (DE) | 2007-10-25 | — | — | WO | claimed |
| US-7173037-B2 | Carbamate-substituted pyrazolopyridines | BAYER HEALTHCARE AG (DE) | 2007-02-06 | — | — | US | claimed |
| EP-1506193-B1 | CARBAMATE-SUBSTITUTED PYRAZOLOPYRIDINES | BAYER HEALTHCARE AG (DE) | 2006-06-21 | — | — | EP | claimed |
| US-20060052397-A1 | Compounds for trearment of cardiovascular disorders and hypotensive agents | BAYER HEALTHCARE AG (DE) | 2006-03-09 | — | — | US | claimed |
| EP-1506193-A1 | CARBAMATE-SUBSTITUTED PYRAZOLOPYRIDINES | Bayer HealthCare AG (DE) | 2005-02-16 | — | — | EP | claimed |
| WO-2003095451-A1 | CARBAMATE-SUBSTITUTED PYRAZOLOPYRIDINES | BAYER HEALTHCARE AG (DE) | 2003-11-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11439628-B2 | Use of non-steroidal mineralocorticoid receptor antagonists alone or in combination for the treatment of muscular or neuromuscular diseases | MC2R, NR3C2, NR3C1 | GUCY1A1 45/4885GUCY1B1 89/4885KCNH2 2108/4885 |
| US-20210121447-A1 | The Use of Non-Steroidal Mineralocorticoid Receptor Antagonists Alone or in Combination for the Treatment of Muscular or Neuromuscular Diseases | MC2R, NR3C2, NR3C1 | GUCY1A1 38/4885GUCY1B1 79/4885KCNH2 1905/4885 |
| US-20100113452-A1 | COMPOUNDS FOR TREATING PULMONARY HYPERTENSION | PTGIR, PTGIS, EDNRB | GUCY1A1 361/4885GUCY1B1 188/4885KCNH2 265/4885 |
| US-20100210643-A1 | sGC STIMULATORS, sGC ACTIVATORS AND COMBINATIONS FOR THE TREATMENT OF UROLOGICAL DISORDERS | PDE5A, PDE3B, PDE3A | GUCY1A1 16/4885GUCY1B1 9/4885KCNH2 2632/4885 |
| US-20060052397-A1 | Compounds for trearment of cardiovascular disorders and hypotensive agents | PDE3A, PDE3B, PDE2A | GUCY1A1 7/4885GUCY1B1 13/4885KCNH2 917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.